Does SKIN pay a dividend and is it safe?

SkinHealth Systems Inc. (Class A) (SKIN) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / SKIN / dividends

QTEX (36) LNSR (18) MBOT (29) DXR (47) ⌘ Pro Terminal →

SkinHealth Systems Inc. (Class A) (SKIN) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is SKIN trading relative to its 50-day, 200-day, and 52-week technical levels?

SKIN last traded at $10.38 (+4.43% on volume of 43,642 shares), positioning the stock -16.43% below its 50-day simple moving average ($12.42) and -37.51% below its 200-day simple moving average ($16.61). Across its 52-week range of $1.24 to $32.90, SKIN sits at the 28.9% percentile with a 14-day RSI of 35.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.08 to $11.68).

$10.38 +4.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.44

SkinHealth Systems Inc. (Class A) (SKIN) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $64.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SKIN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SKIN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, SkinHealth Systems Inc. (Class A) (NASDAQ: SKIN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $10.38 (+4.43% 1D, market cap $64.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SKIN ranks #725 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SKIN compare to QTEX and LNSR in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), SKIN carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 65.3%, and ROIC of -26.9%. By comparison, QTEX (QTREX Quantum Ltd.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $68.3M) and LNSR (LENSAR Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $71.7M). Among the 5-stock peer group, SKIN leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SKIN?

▼

Per SKIN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818093), SkinHealth Systems Inc. (Class A) generated $300.8M in revenue (-10.0% YoY), -$9.5M in net income, and $37.2M in free cash flow against $499.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.44 (+0.61%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 12.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SKIN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY SKIN SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 12.4% FCF Margin ($37.2M FCF) & 65.3% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (25% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$10.50+0.5% Next Q

Q2 (-2Q)

Grade E$10.55-0.3% Next Q

Q3 (-1Q)

Grade E$10.52-1.3% Next Q

Current

Grade E$10.38-9.2% Hist 90D α

Trajectory: D (40) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SKIN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SKIN currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.42) and Max Pain ($10.90) forces dealer call-delta covering toward $34.55.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SKIN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SKIN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SKIN)

✓Walkthrough of SKIN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SKIN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -42.33%🛡️ HOLDING TREND SUPPORT

2026-11-03O $10.15H $10.38L $9.94C $10.38VOL 75.3K

RES: $12.23SUP: $9.58SMA50: $12.42SMA200: $16.61

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SKIN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SKIN Butterfly Map → + Track SKIN →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -10.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SKIN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SKIN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SKIN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SKIN)

Health Care Rank #725 of 1015 ⚔️ QTEX vs SKIN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SKIN vs. QTEX, LNSR, MBOT, DXR)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, SkinHealth Systems Inc. (Class A) (SKIN) ranks #725 by composite RQD confidence (32/100, grade E) and #708 by equity capitalization ($64.7M). Within this direct 5-issuer industry benchmark cohort, SKIN leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and — gross margin. DXR currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with SKIN at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SKIN ACTIVE SkinHealth Systems Inc. (Class A)	E	32/100	—	65.3%	-26.9%	+4.43%	$64.7M	Benchmark Subject
QTEX QTREX Quantum Ltd.	D-	36/100	—	0.7%	-35.0%	-8.20%	$68.3M	/qtex-vs-skin →
LNSR LENSAR Inc.	E	18/100	—	39.4%	-35.0%	-2.91%	$71.7M	/lnsr-vs-skin →
MBOT Microbot Medical Inc.	E	29/100	—	—	-15.8%	-4.59%	$73.2M	/mbot-vs-skin →
DXR Daxor Corporation	D	47/100	—	—	—	-2.17%	$53.7M	/dxr-vs-skin →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001818093 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SkinHealth Systems Inc. (Class A) (SKIN) reported GAAP revenue of $300.8M (-10.0% vs. FY2024 revenue of $334.3M , and -24.4% cumulative change since FY2023) , GAAP net income of -$9.5M, operating cash flow of $37.5M, and free cash flow of $37.2M (+141.8% YoY). On the balance sheet, SKIN closed FY2025 with $499.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$300.8M	-$9.5M	$37.5M	$37.2M	$499.8M	—
FY2024 (FY)	2024-12-31	$334.3M	-$29.1M	$16.1M	$15.4M	$685.7M	—
FY2023 (FY)	2023-12-31	$398.0M	-$100.1M	$21.8M	$21.8M	—	—

3. SKIN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SKIN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SKIN compare to QTEX and LNSR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SKIN?

Where is SKIN trading relative to its 50-day, 200-day, and 52-week technical levels?

SKIN last traded at $10.38 (+4.43% on volume of 43,642 shares), positioning the stock -16.43% below its 50-day simple moving average ($12.42) and -37.51% below its 200-day simple moving average ($16.61). Across its 52-week range of $1.24 to $32.90, SKIN sits at the 28.9% percentile with a 14-day RSI of 35.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.08 to $11.68).

Direct Sub-Reports: SKIN RQD Cockpit SKIN 12M Forecast SKIN Earnings & Move SKIN Dividends & DRIP SKIN Insiders & 13F SKIN Whale Options SKIN Profit Sankey SKIN News & Why

ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ SEC XBRL & RQD VERIFIED

SKIN — SkinHealth Systems Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

SkinHealth Systems Inc. (Class A) (SKIN) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $10.38 (+4.43% 1D, market capitalization $64.7M).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -26.9%, gross margin of 65.3%, operating margin of -6.9%, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 6/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (Class A) is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry..1B. Per the market data, gross margin is 65.3%, indicating a high gross-profit share of revenue before operating costs.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), SkinHealth Systems Inc. (Class A) (SKIN) reported $300.8M in annual revenue (up from $334.3M in FY2024, -10.0% YoY) and -$9.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($398.0M revenue, -$100.1M net income) through FY2025, SKIN scaled operating cash flow to $37.5M and free cash flow to $37.2M, backed by $499.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.24 – $32.90 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -6.9% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream links are recorded, and no proprietary signals are listed. Second-order ripples therefore cannot be traced from the provided data. A prospective investor should note that the reverse split and Nasdaq compliance activity are the principal non-financial events in the feed, and that the Q3 2026 results call is the next scheduled informational event.

Key Question #1: Can SKIN sustain or expand its -6.9% operating margin and -26.9% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $300.8M and free cash flow of $37.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is SKIN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SKIN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SkinHealth Systems Inc. (Class A) (SKIN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SKIN Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 23h ago

SkinHealth Systems Inc. (SKIN) Soars 9.0%: Is Further Upside Left in the Stock?

Yahoo Finance report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 1d ago

SkinHealth Systems (SKIN) Stock Fair Value Falls After Reverse Split And Hold Ratings

Yahoo Finance report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Quiver Quantitative • 1d ago

SkinHealth Systems Announces 1-for-20 Reverse Stock Split to Regain Nasdaq Compliance

Quiver Quantitative report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com UK • 1d ago

SkinHealth Systems approves 1-for-20 reverse stock split By Investing.com

Investing.com UK report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

SkinHealth Systems to Implement 1-for-20 Reverse Stock Split

Yahoo Finance report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Quiver Quantitative • 1d ago

SkinHealth Systems Announces Date for Third Quarter 2026 Financial Results Conference Call

Quiver Quantitative report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Pluang • 1d ago

SkinHealth Systems announces 1-for-20 reverse s...

Pluang report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

SkinHealth Systems Inc. (SKIN) Expected to Beat Earnings Estimates: Should You Buy?

Yahoo Finance report covering SkinHealth Systems Inc. (Class A) (SKIN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SKIN Bull vs. Bear Conversation Board — What's Your Call at $10.38?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SKIN 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $13.12 (+32.0%)

📌 Pinned Debate

Reported FCF stayed positive at $37.2M in FY 2025 while operating losses narrowed to -$20.8M from -$130.9M in FY 2023.

Long SKIN at $9.94 targeting $13.12. Reported FCF stayed positive at $37.2M in FY 2025 while operating losses narrowed to -$20.8M from -$130.9M in FY 2023.. Institutional whale score is 3/20 and the risk/reward vs. the $1.80 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@QuantViper Agree on the RQD 32/100 quality, though with 1.0 beta I'm scaling in with half-size at $9.94 and keeping dry powder in case we test $9.24.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $7.85 (-21.0%)

Spot @ $9.94

An Altman Z-Score of 0.2 and ROIC of -26.9% signal a fragile balance sheet and negative returns on invested capital.

Sitting on the sidelines or leaning short SKIN above $9.94. An Altman Z-Score of 0.2 and ROIC of -26.9% signal a fragile balance sheet and negative returns on invested capital.. Until Fundamental Cash Engine (8/20) and FCF yield (0.0%) inflect higher, upside is capped near $32.90.